Evaluation of the incidence, predictors, risk assessment scores and outcomes of thromboembolism in a cohort of Egyptian NHL patients - Real World Experience
Non-Hodgkin’s Lymphoma (NHL) is the most common subtype of lymphoma. The incidence of venous thromboembolism (VTE) in aggressive NHL was estimated recently to be 11%. Several risk assessment scores and factors are available to help identify cancer patients at risk for developing VTE. Patients with a...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2024-10, Vol.103 (10), p.4271-4283 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4283 |
|---|---|
| container_issue | 10 |
| container_start_page | 4271 |
| container_title | Annals of hematology |
| container_volume | 103 |
| creator | El-Ashwah, Shaimaa Elashwah, Salma Khaled, Omnia Ghanem, Ahmed A. AboElfarh, Hadeer Elsaeed Selim, Ramadan Ayman Mansour, Reham Osama Shaaban, Yasmine |
| description | Non-Hodgkin’s Lymphoma (NHL) is the most common subtype of lymphoma. The incidence of venous thromboembolism (VTE) in aggressive NHL was estimated recently to be 11%. Several risk assessment scores and factors are available to help identify cancer patients at risk for developing VTE. Patients with a pathologically confirmed diagnosis of NHL were identified at the Oncology Center of Mansoura University. The study included 777 patients: 719 with DLBCL-NOS, 26 with Anaplastic-B-cell, and 32 with T-cell-rich-NHL. Data were retrospectively collected from electronic medical records, including clinical, radiological, and laboratory information related to VTE and NHL. The median age at NHL diagnosis was 53 years, (range: 18–98). There was a male predominance, 51.4% of the cases. At initial lymphoma diagnosis, VTE was identified in 46 (5.9%) patients, and 61 (7.9%) patients experienced VTE while undergoing chemotherapy. According to logistic regression analysis, a PS (performance status) ≥ 2, bulky lesions, and mediastinal masses were significant predictors of VTE at presentation, with
P
-values of 0.022, 0.002, and |
| doi_str_mv | 10.1007/s00277-024-05904-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11512909</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3121050277</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-d742d47d1af6218b5fd8143826b9e5c3b48965b879e3fd50331ae4cd707a72583</originalsourceid><addsrcrecordid>eNp9UcuKFDEUDaI4besPuJCAGxdTmmdXspJhaB2hURDFZUglqe6MVZUyt2pw_sWPNTU9jo-FgRAu9-Tcc-5B6CklLykh9SsghNV1RZioiNREVOoeWlHBWSmVuI9WRHNdyXJO0COAS0IoU4I9RCdcU0qo1iv0Y3tlu9lOMQ04tXg6BBwHF30YXDjFYw4-uillOMU5wldsAQJAH4YJg0s5ALaDx2meXOpLccOQU9-kUG4XoS9s2GKXDilPS3u7vx6naAf8_mKHxzK3UAGu8MdgO_wl5c7j7fcx5LgIeIwetLaD8OT2XaPPb7afzi-q3Ye3787PdpXjcjNVvhbMi9pT224YVY1svSprUGzT6CAdb4TSG9moWgfeekk4pzYI52tS25pJxdfo9ZF3nJs-eFc0ZduZMcfe5muTbDR_d4Z4MPt0ZSiVlOmy5jV6ccuQ07c5wGT6CC50nR1CmsFworRSTLAF-vwf6GWa81D8GU4ZJXIJtaDYEeVyAsihvVNDiVnSN8f0TUnf3KRvFh_P_vRx9-VX3AXAjwAorWEf8u_Z_6H9CQSGvO0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3121050277</pqid></control><display><type>article</type><title>Evaluation of the incidence, predictors, risk assessment scores and outcomes of thromboembolism in a cohort of Egyptian NHL patients - Real World Experience</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>El-Ashwah, Shaimaa ; Elashwah, Salma ; Khaled, Omnia ; Ghanem, Ahmed A. ; AboElfarh, Hadeer Elsaeed ; Selim, Ramadan Ayman ; Mansour, Reham Osama ; Shaaban, Yasmine</creator><creatorcontrib>El-Ashwah, Shaimaa ; Elashwah, Salma ; Khaled, Omnia ; Ghanem, Ahmed A. ; AboElfarh, Hadeer Elsaeed ; Selim, Ramadan Ayman ; Mansour, Reham Osama ; Shaaban, Yasmine</creatorcontrib><description>Non-Hodgkin’s Lymphoma (NHL) is the most common subtype of lymphoma. The incidence of venous thromboembolism (VTE) in aggressive NHL was estimated recently to be 11%. Several risk assessment scores and factors are available to help identify cancer patients at risk for developing VTE. Patients with a pathologically confirmed diagnosis of NHL were identified at the Oncology Center of Mansoura University. The study included 777 patients: 719 with DLBCL-NOS, 26 with Anaplastic-B-cell, and 32 with T-cell-rich-NHL. Data were retrospectively collected from electronic medical records, including clinical, radiological, and laboratory information related to VTE and NHL. The median age at NHL diagnosis was 53 years, (range: 18–98). There was a male predominance, 51.4% of the cases. At initial lymphoma diagnosis, VTE was identified in 46 (5.9%) patients, and 61 (7.9%) patients experienced VTE while undergoing chemotherapy. According to logistic regression analysis, a PS (performance status) ≥ 2, bulky lesions, and mediastinal masses were significant predictors of VTE at presentation, with
P
-values of 0.022, 0.002, and < 0.001, respectively. Meanwhile, NHL patients who developed VTE during chemotherapy had significantly poorer PS, higher absolute neutrophilic counts (ANC), neutrophil/lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and lactate dehydrogenase (LDH) levels than lymphoma patients without VTE, with
P
-values of 0.003, 0.034, 0.049, 0.01 and 0.007, respectively, as determined by multivariate analysis. The ROC curve identified the cut-off values of 4.875 × 10
9
/L for ANC, 2.985 for NLR, 144.85 for PLR, and 417.5 U/L for LDH as potential markers for predicting VTE in NHL patients. Patients with a PS ≥ 2 and values exceeding these cut-offs for ANC, NLR, and PLR experienced significantly higher incidences of VTE than other groups, with
P-
values of 0.003, < 0.001, < 0.001, and < 0.001, respectively. At the end of the follow-up, the overall survival was significantly shortened by VTE occurring during chemotherapy, hypoalbuminemia, intermediate-high and high international prognostic index (IPI) scores (intermediate-high and high), responses other than CR and relapse, all with
P-
values < 0.05. ECOG PS and Inflammatory markers such as NLR, PLR, and neutrophilic count could serve as predictors of the development of thrombotic events in patients with NHL-DLBCL. Additionally, the occurrence of VTE during chemotherapy is an independent poor prognostic marker for overall survival (OS).</description><identifier>ISSN: 0939-5555</identifier><identifier>ISSN: 1432-0584</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-024-05904-8</identifier><identifier>PMID: 39110199</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Chemotherapy ; Egypt - epidemiology ; Female ; Hematology ; Humans ; Incidence ; Lymphoma ; Lymphoma, Non-Hodgkin - complications ; Lymphoma, Non-Hodgkin - drug therapy ; Lymphoma, Non-Hodgkin - epidemiology ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Prognosis ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Thromboembolism ; Venous Thromboembolism - diagnosis ; Venous Thromboembolism - epidemiology ; Venous Thromboembolism - etiology ; Young Adult</subject><ispartof>Annals of hematology, 2024-10, Vol.103 (10), p.4271-4283</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2024 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c356t-d742d47d1af6218b5fd8143826b9e5c3b48965b879e3fd50331ae4cd707a72583</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-024-05904-8$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-024-05904-8$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39110199$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>El-Ashwah, Shaimaa</creatorcontrib><creatorcontrib>Elashwah, Salma</creatorcontrib><creatorcontrib>Khaled, Omnia</creatorcontrib><creatorcontrib>Ghanem, Ahmed A.</creatorcontrib><creatorcontrib>AboElfarh, Hadeer Elsaeed</creatorcontrib><creatorcontrib>Selim, Ramadan Ayman</creatorcontrib><creatorcontrib>Mansour, Reham Osama</creatorcontrib><creatorcontrib>Shaaban, Yasmine</creatorcontrib><title>Evaluation of the incidence, predictors, risk assessment scores and outcomes of thromboembolism in a cohort of Egyptian NHL patients - Real World Experience</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>Non-Hodgkin’s Lymphoma (NHL) is the most common subtype of lymphoma. The incidence of venous thromboembolism (VTE) in aggressive NHL was estimated recently to be 11%. Several risk assessment scores and factors are available to help identify cancer patients at risk for developing VTE. Patients with a pathologically confirmed diagnosis of NHL were identified at the Oncology Center of Mansoura University. The study included 777 patients: 719 with DLBCL-NOS, 26 with Anaplastic-B-cell, and 32 with T-cell-rich-NHL. Data were retrospectively collected from electronic medical records, including clinical, radiological, and laboratory information related to VTE and NHL. The median age at NHL diagnosis was 53 years, (range: 18–98). There was a male predominance, 51.4% of the cases. At initial lymphoma diagnosis, VTE was identified in 46 (5.9%) patients, and 61 (7.9%) patients experienced VTE while undergoing chemotherapy. According to logistic regression analysis, a PS (performance status) ≥ 2, bulky lesions, and mediastinal masses were significant predictors of VTE at presentation, with
P
-values of 0.022, 0.002, and < 0.001, respectively. Meanwhile, NHL patients who developed VTE during chemotherapy had significantly poorer PS, higher absolute neutrophilic counts (ANC), neutrophil/lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and lactate dehydrogenase (LDH) levels than lymphoma patients without VTE, with
P
-values of 0.003, 0.034, 0.049, 0.01 and 0.007, respectively, as determined by multivariate analysis. The ROC curve identified the cut-off values of 4.875 × 10
9
/L for ANC, 2.985 for NLR, 144.85 for PLR, and 417.5 U/L for LDH as potential markers for predicting VTE in NHL patients. Patients with a PS ≥ 2 and values exceeding these cut-offs for ANC, NLR, and PLR experienced significantly higher incidences of VTE than other groups, with
P-
values of 0.003, < 0.001, < 0.001, and < 0.001, respectively. At the end of the follow-up, the overall survival was significantly shortened by VTE occurring during chemotherapy, hypoalbuminemia, intermediate-high and high international prognostic index (IPI) scores (intermediate-high and high), responses other than CR and relapse, all with
P-
values < 0.05. ECOG PS and Inflammatory markers such as NLR, PLR, and neutrophilic count could serve as predictors of the development of thrombotic events in patients with NHL-DLBCL. Additionally, the occurrence of VTE during chemotherapy is an independent poor prognostic marker for overall survival (OS).</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Chemotherapy</subject><subject>Egypt - epidemiology</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Incidence</subject><subject>Lymphoma</subject><subject>Lymphoma, Non-Hodgkin - complications</subject><subject>Lymphoma, Non-Hodgkin - drug therapy</subject><subject>Lymphoma, Non-Hodgkin - epidemiology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Thromboembolism</subject><subject>Venous Thromboembolism - diagnosis</subject><subject>Venous Thromboembolism - epidemiology</subject><subject>Venous Thromboembolism - etiology</subject><subject>Young Adult</subject><issn>0939-5555</issn><issn>1432-0584</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9UcuKFDEUDaI4besPuJCAGxdTmmdXspJhaB2hURDFZUglqe6MVZUyt2pw_sWPNTU9jo-FgRAu9-Tcc-5B6CklLykh9SsghNV1RZioiNREVOoeWlHBWSmVuI9WRHNdyXJO0COAS0IoU4I9RCdcU0qo1iv0Y3tlu9lOMQ04tXg6BBwHF30YXDjFYw4-uillOMU5wldsAQJAH4YJg0s5ALaDx2meXOpLccOQU9-kUG4XoS9s2GKXDilPS3u7vx6naAf8_mKHxzK3UAGu8MdgO_wl5c7j7fcx5LgIeIwetLaD8OT2XaPPb7afzi-q3Ye3787PdpXjcjNVvhbMi9pT224YVY1svSprUGzT6CAdb4TSG9moWgfeekk4pzYI52tS25pJxdfo9ZF3nJs-eFc0ZduZMcfe5muTbDR_d4Z4MPt0ZSiVlOmy5jV6ccuQ07c5wGT6CC50nR1CmsFworRSTLAF-vwf6GWa81D8GU4ZJXIJtaDYEeVyAsihvVNDiVnSN8f0TUnf3KRvFh_P_vRx9-VX3AXAjwAorWEf8u_Z_6H9CQSGvO0</recordid><startdate>20241001</startdate><enddate>20241001</enddate><creator>El-Ashwah, Shaimaa</creator><creator>Elashwah, Salma</creator><creator>Khaled, Omnia</creator><creator>Ghanem, Ahmed A.</creator><creator>AboElfarh, Hadeer Elsaeed</creator><creator>Selim, Ramadan Ayman</creator><creator>Mansour, Reham Osama</creator><creator>Shaaban, Yasmine</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20241001</creationdate><title>Evaluation of the incidence, predictors, risk assessment scores and outcomes of thromboembolism in a cohort of Egyptian NHL patients - Real World Experience</title><author>El-Ashwah, Shaimaa ; Elashwah, Salma ; Khaled, Omnia ; Ghanem, Ahmed A. ; AboElfarh, Hadeer Elsaeed ; Selim, Ramadan Ayman ; Mansour, Reham Osama ; Shaaban, Yasmine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-d742d47d1af6218b5fd8143826b9e5c3b48965b879e3fd50331ae4cd707a72583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Chemotherapy</topic><topic>Egypt - epidemiology</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Incidence</topic><topic>Lymphoma</topic><topic>Lymphoma, Non-Hodgkin - complications</topic><topic>Lymphoma, Non-Hodgkin - drug therapy</topic><topic>Lymphoma, Non-Hodgkin - epidemiology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Thromboembolism</topic><topic>Venous Thromboembolism - diagnosis</topic><topic>Venous Thromboembolism - epidemiology</topic><topic>Venous Thromboembolism - etiology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>El-Ashwah, Shaimaa</creatorcontrib><creatorcontrib>Elashwah, Salma</creatorcontrib><creatorcontrib>Khaled, Omnia</creatorcontrib><creatorcontrib>Ghanem, Ahmed A.</creatorcontrib><creatorcontrib>AboElfarh, Hadeer Elsaeed</creatorcontrib><creatorcontrib>Selim, Ramadan Ayman</creatorcontrib><creatorcontrib>Mansour, Reham Osama</creatorcontrib><creatorcontrib>Shaaban, Yasmine</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>El-Ashwah, Shaimaa</au><au>Elashwah, Salma</au><au>Khaled, Omnia</au><au>Ghanem, Ahmed A.</au><au>AboElfarh, Hadeer Elsaeed</au><au>Selim, Ramadan Ayman</au><au>Mansour, Reham Osama</au><au>Shaaban, Yasmine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of the incidence, predictors, risk assessment scores and outcomes of thromboembolism in a cohort of Egyptian NHL patients - Real World Experience</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2024-10-01</date><risdate>2024</risdate><volume>103</volume><issue>10</issue><spage>4271</spage><epage>4283</epage><pages>4271-4283</pages><issn>0939-5555</issn><issn>1432-0584</issn><eissn>1432-0584</eissn><abstract>Non-Hodgkin’s Lymphoma (NHL) is the most common subtype of lymphoma. The incidence of venous thromboembolism (VTE) in aggressive NHL was estimated recently to be 11%. Several risk assessment scores and factors are available to help identify cancer patients at risk for developing VTE. Patients with a pathologically confirmed diagnosis of NHL were identified at the Oncology Center of Mansoura University. The study included 777 patients: 719 with DLBCL-NOS, 26 with Anaplastic-B-cell, and 32 with T-cell-rich-NHL. Data were retrospectively collected from electronic medical records, including clinical, radiological, and laboratory information related to VTE and NHL. The median age at NHL diagnosis was 53 years, (range: 18–98). There was a male predominance, 51.4% of the cases. At initial lymphoma diagnosis, VTE was identified in 46 (5.9%) patients, and 61 (7.9%) patients experienced VTE while undergoing chemotherapy. According to logistic regression analysis, a PS (performance status) ≥ 2, bulky lesions, and mediastinal masses were significant predictors of VTE at presentation, with
P
-values of 0.022, 0.002, and < 0.001, respectively. Meanwhile, NHL patients who developed VTE during chemotherapy had significantly poorer PS, higher absolute neutrophilic counts (ANC), neutrophil/lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and lactate dehydrogenase (LDH) levels than lymphoma patients without VTE, with
P
-values of 0.003, 0.034, 0.049, 0.01 and 0.007, respectively, as determined by multivariate analysis. The ROC curve identified the cut-off values of 4.875 × 10
9
/L for ANC, 2.985 for NLR, 144.85 for PLR, and 417.5 U/L for LDH as potential markers for predicting VTE in NHL patients. Patients with a PS ≥ 2 and values exceeding these cut-offs for ANC, NLR, and PLR experienced significantly higher incidences of VTE than other groups, with
P-
values of 0.003, < 0.001, < 0.001, and < 0.001, respectively. At the end of the follow-up, the overall survival was significantly shortened by VTE occurring during chemotherapy, hypoalbuminemia, intermediate-high and high international prognostic index (IPI) scores (intermediate-high and high), responses other than CR and relapse, all with
P-
values < 0.05. ECOG PS and Inflammatory markers such as NLR, PLR, and neutrophilic count could serve as predictors of the development of thrombotic events in patients with NHL-DLBCL. Additionally, the occurrence of VTE during chemotherapy is an independent poor prognostic marker for overall survival (OS).</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>39110199</pmid><doi>10.1007/s00277-024-05904-8</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2024-10, Vol.103 (10), p.4271-4283 |
| issn | 0939-5555 1432-0584 1432-0584 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11512909 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adolescent Adult Aged Aged, 80 and over Chemotherapy Egypt - epidemiology Female Hematology Humans Incidence Lymphoma Lymphoma, Non-Hodgkin - complications Lymphoma, Non-Hodgkin - drug therapy Lymphoma, Non-Hodgkin - epidemiology Male Medicine Medicine & Public Health Middle Aged Oncology Prognosis Retrospective Studies Risk Assessment Risk Factors Thromboembolism Venous Thromboembolism - diagnosis Venous Thromboembolism - epidemiology Venous Thromboembolism - etiology Young Adult |
| title | Evaluation of the incidence, predictors, risk assessment scores and outcomes of thromboembolism in a cohort of Egyptian NHL patients - Real World Experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T03%3A41%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20the%20incidence,%20predictors,%20risk%20assessment%20scores%20and%20outcomes%20of%20thromboembolism%20in%20a%20cohort%20of%20Egyptian%20NHL%20patients%20-%20Real%20World%20Experience&rft.jtitle=Annals%20of%20hematology&rft.au=El-Ashwah,%20Shaimaa&rft.date=2024-10-01&rft.volume=103&rft.issue=10&rft.spage=4271&rft.epage=4283&rft.pages=4271-4283&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-024-05904-8&rft_dat=%3Cproquest_pubme%3E3121050277%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3121050277&rft_id=info:pmid/39110199&rfr_iscdi=true |